- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05241561
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients (Cabo-POLARIS)
Open-label, Multicenter, Prospective Phase 2 Study to Evaluate the Duration of Treatment With Cabozantinib Among Patients With Metastatic or Locally Advanced Renal Cell Carcinoma on Hemodialysis (HD).
Among patients with renal cell carcinoma (RCC), 2.7 to 4.7 % of patients are at risk of progressing to dialysis or transplantation after partial and radical nephrectomy respectively. Of note, similar risk factors can be seen in both disease: RCC and renal impairment leading to dialysis. Currently, three types of systemic therapies (ST) are mainly used among patients with metastatic renal cell carcinoma (mRCC): anti-angiogenics (mostly tyrosine kinase inhibitors and bevacizumab), mTOR inhibitors and immune checkpoint inhibitor.
ST prescription for patients undergoing HD may be more dangerous than in other patients. This is partially explained by the fact that several adverse events can be induced by both the ST and HD e.g. thromboembolic disease, or hypertension.
Patients in HD are usually excluded from major clinical trials and available data concerning safety and activity of ST in this specific population are lacking. In most cases, drugs' label is driven by the eligibility criteria of large randomized phase 3 trials that exclude this type of patients. The main source of information for these patients comes from academic publications of patients' cases or small cohorts, but they are not included within the drug label. Moreover, no clear guidelines are given by savant societies regarding those patients.
It is known that patients with HD are at high risk of specific adverse events that can sometimes overlap with the safety profile of anti-cancer drugs: thromboembolic complications, cardio-vascular comorbidities, hematologic and metabolic abnormalities.
Having a dedicated clinical trial to this particular population would definitely help the community to improve the care of HD patients by getting prospective data in order to increase the level of evidence and therefore to optimize anticancer drug use in this specific population.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Oczekiwany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Elise Robert
- Numer telefonu: +33 3 81 66 81 66
- E-mail: e1robert@chu-besancon.fr
Lokalizacje studiów
-
-
-
Besançon, Francja
- Centre Hospitalier Universitaire de Besancon
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Main Inclusion Criteria:
- Documented histological diagnosis of advanced or metastatic renal cell cancer with a clear-cell or papillary component.
- Must have received at least one prior line of systemic therapy.
- Undergoing haemodialysis for more than 3 months without major complications that might confound the results of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- Recovery to baseline or ≤ Grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, unless AE(s) are considered clinically nonsignificant by the investigator and/or stable on supportive therapy.
- Age eighteen years or older on the day of consent.
- Karnofsky Performance Status (KPS) score of ≥ 70%.
- Adequate organ and marrow function.
Main exclusion Criteria:
- Prior treatment with cabozantinib.
- Kidney cancer without clear-cell or papillary component.
- Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before cabozantinib initiation.
- Receipt of any type of anticancer antibody within 2 weeks before randomization. For investigational antibody the delay is 4 weeks.
5 Major surgery within 4 weeks or major radiotherapy within 2 weeks prior to starting cabozantinib. Previous palliative radiotherapy (≤ 10 fractions) for metastatic lesions is permitted, provided that this has been completed at least 48 hours prior to starting cabozantinib. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
6. Known brain metastases or spinal compression unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 6 weeks before randomization. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of randomization. Patients with a past history of meningeal carcinomatosis are not eligible.
7. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
7a. Cardiovascular disorders
7b Active infection requiring systemic treatment.
7c. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation
7d. Clinically significant haematuria, hematemesis, or haemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary haemorrhage) within 3 months before randomization.
7e. Cavitating pulmonary lesion(s) or known endobronchial disease manifestation.
7f. Lesions invading major pulmonary blood vessels. 7g. Other clinically significant disorders.
8. Corrected QT interval > 480 msec within 1 month before randomization. Three ECGs must be performed. If the average of these three consecutive results for QTcF is ≤ 480 msec, the subject meets eligibility in this regard.
9. - Existence of a past history of cancer within 3 years prior to inclusion into the study (excluding cured localized cancer such as non-melanomatous skin cancers, superficial bladder cancers, or in situ for breast or uterine cervical cancer, and localized prostate cancer without biochemical PSA relapse).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Kabozantynib
|
Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety. At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile.
biomonitoring and pharmacokinetics
FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
rate of patients permanently discontinuing for any reason cabozantinib at 6 months after initiation of treatment
Ramy czasowe: 6 months
|
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
przeżycie wolne od progresji choroby (PFS)
Ramy czasowe: 24 miesiące
|
24 miesiące
|
całkowity czas przeżycia (OS)
Ramy czasowe: 24 miesiące
|
24 miesiące
|
przeżycie wolne od progresji
Ramy czasowe: 24 miesiące
|
24 miesiące
|
rate of patients permanently discontinuing cabozantinib at 6 months after initiation of treatment due to toxicity
Ramy czasowe: 6 months
|
6 months
|
Absolute and relative frequency of dose reductions and temporary or permanent discontinuation of cabozantinib
Ramy czasowe: 24 months
|
24 months
|
total duration of treatment with cabozantinib
Ramy czasowe: 24 months
|
24 months
|
objective response rate
Ramy czasowe: 24 months
|
24 months
|
overall safety profile of cabozantinib
Ramy czasowe: 24 months
|
24 months
|
time to deterioration in quality of life on cabozantinib
Ramy czasowe: 24 months
|
24 months
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Oczekiwany)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2021/653
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak Nerki
-
Northwestern UniversityUniversity of Wisconsin, StoutZakończonyPostrzeganie klinik Skin of Color u AfroamerykanówStany Zjednoczone
-
Kecioren Education and Training HospitalZakończony
-
University of BernUniversity Hospital Inselspital, BerneZakończonyNeuroscience of Dreaming, ZdrowySzwajcaria
-
Hôpital Européen MarseilleZakończonyKrytyczna opieka | Elektrolity | Systemy Point-of-CareFrancja
-
Queens College, The City University of New YorkRekrutacyjnyPublikacja artykułów przesłanych do American Journal of Public HealthStany Zjednoczone
-
Johann Wolfgang Goethe University HospitalZakończonySystemy Point-of-Care | Krew | Analiza, historia zdarzeńNiemcy
-
Abramson Cancer Center of the University of PennsylvaniaWycofanePacjenci z chorobą nowotworową poddawani przeszczepowi komórek macierzystych (RCT of ACP for Transplant)
-
Umraniye Education and Research HospitalRekrutacyjnyPilonidal Sinus of Natal Cleft | Zatoka włosowa bez ropniaIndyk
-
Swansea UniversityZakończonyA Bite of ACT' (BOA) Terapia akceptacji i zaangażowania Internetowy kurs psychoedukacyjny | Kontrola listy oczekującychZjednoczone Królestwo
-
Aarhus University HospitalNieznanyUltrasonografia Point of Care w Oddziale Ratunkowym.Dania